The development of brain metastases occurs in 10–20% of all patients with cancer. Brain
metastases portend poor survival and contribute to increased cancer mortality and morbidity …

Introduction In order to standardize and expedite molecular biomarker testing, we
implemented reflex ordered testing of targeted gene alterations in newly diagnosed lung …

Introduction Studies are yet to characterize the differences in molecular profiles of lung
adenocarcinoma (LUAD) among divergent ethnic groups. Herein, we conducted …

Background Isolated reports are inconsistent regarding the risk of venous thromboembolism
(VTE) in patients with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung …

Introduction RET rearrangements are an emerging targetable oncogenic fusion driver in
NSCLC. However, the natural history of disease and activity of different classes of systemic …

Objectives: To identify a computed tomography (CT)-based radiomic signature for predicting
progression-free survival (PFS) in stage IV anaplastic lymphoma kinase (ALK)-positive non …

Background Epithelioid inflammatory myofibroblastic sarcoma (eIMS) is characterised by
perinuclear ALK localisation, CD30 expression and early relapse despite crizotinib …

Introduction The phase II, single-arm ASCEND-3 study assessed the efficacy and safety of
ceritinib in anaplastic lymphoma kinase (ALK) inhibitor (ALKi)–naive patients with ALK …

Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint
inhibitor (ICI) treatment efficacy. The clinical efficacy of ICIs for non-small-cell lung cancer …

Abstract Background: Immune checkpoint inhibitors (ICIs) emerged as the preferred therapy
in advanced lung cancer, understanding the treatment-and immune-related adverse events …